OPKO Health. has been granted a patent for CTP-modified human growth hormone polypeptides and their pharmaceutical formulations. The patent includes a method for maintaining normal IGF-1 levels in growth hormone deficient prepubertal pediatric subjects through a specific dosing regimen of the modified polypeptide. GlobalData’s report on OPKO Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on OPKO Health, Peptide pharmacophores was a key innovation area identified from patents. OPKO Health's grant share as of June 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.
Ctp-modified human growth hormone for pediatric igf-1 maintenance
The patent US12029780B2 outlines a method for maintaining insulin-like growth factor (IGF-1) levels within a normal therapeutic range in growth hormone-deficient prepubertal pediatric subjects. The method involves administering a glycosylated polypeptide known as a CTP-modified human growth hormone (hGH) polypeptide, which includes specific amino terminal and carboxy terminal chorionic gonadotropin peptides. The administration is specified as a once-weekly dose of 0.66 mg/kg/week, aimed at achieving IGF-1 levels that fall within ±2 standard deviations of the average levels found in non-deficient subjects. The claims also detail the timing of IGF-1 level assessments, indicating that levels should be tested four days post-administration and maintained within the therapeutic range for durations ranging from two weeks to six months.
Further claims elaborate on the expected outcomes of the treatment, including a minimum six-month annualized height velocity increase of at least 12.25 cm, with higher thresholds of 13.48 cm and 14.37 cm specified in subsequent claims. The patent also addresses the maintenance of IGF-1 levels within the therapeutic range for varying time frames, including four months and six months. Additionally, it identifies the target population as naïve growth hormone-deficient pediatric subjects and provides specific intervals for maintaining IGF-1 levels post-administration. The CTP-modified hGH polypeptide is encoded by a defined nucleic acid sequence, further detailing the molecular basis of the treatment. This patent presents a comprehensive approach to managing growth hormone deficiency in pediatric patients, focusing on both biochemical and growth metrics.
To know more about GlobalData’s detailed insights on OPKO Health, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
